Hepsin inhibits the cell growth of endometrial cancer

International Journal of Molecular Medicine

Volumn 22, Issue 3, 2008, Pages 389-397

  Nakamura, Keiichiro ^a   Takamoto, Norio ^a   Abarzua, Fernando ^a   Hongo, Atsushi ^a   Kodama, Junichi ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cell cycle; Endometrial cancer; Hepsin

Indexed keywords

AGAR; CYCLIN A; CYCLIN B; HEPSIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; STRATIFIN; PROTEIN 14 3 3; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG SCREENING; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

14-3-3 PROTEINS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53049093615     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000035     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Leytus SP, Loeb KR, Hagen FS, Kurachi K and Davie EW: A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 27: 1067-1074, 1988.
3. Srikantan V, Valladares M, Rhim JS, Moul JW and Srivastava S: Hepsin inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62: 6812-6816, 2002.
4. Nakamura K, Nasu Y, Hongo A, Matsuo T, Kodama J, et al: Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int J Oncol 28: 393-398, 2006.
5. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
6. Golubnitschaja O, Moenkemann H, Kim K and Mozaffari MS: DNA damage and expression of checkpoint genes p21 (WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem Pharmacol 66: 511-517, 2003.
7. Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326, 2002.
8. Chow JP, Sin WY, Fung TK, Chan WM, Lau A, Arooz T, et al: DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase. Mol Biol Cell 14: 3989-4002, 2003.
9. Evans DL and Mansel RE: Molecular evolution and secondary structural conservation in the B-cell lymphoma leukemia 2 (bcl-2) family of proto-oncogene products. J Mol Evol 41: 775-783, 1995.
10. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR and Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996.
11. Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478, 1999.
12. Basu A and Haldar S: Identification of a novel Bel-xL phosphorylation site regulating the sensitivity of taxol- or 2- methoxyestradiol-induced apoptosis. FEBS Lett 538: 41-47, 2003.
13. Nishida M, Kasahara K, Kaneko M, Iwasaki H and Hayashi K: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37: 1103-1111, 1985.
14. Kuramoto H, Tamura S and Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114: 1012-1019, 1972.
15. Isaka K, Nishi H, Sagawa Y, Nakada T, Osakabe Y, Serizawa H, et al: Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma. Cancer Genet Cytogenet 141: 20-25, 2003.
16. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, et al: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and micro-dissected prostate tissue. Am J Pathol 160: 2169-2180, 2002.
17. Schmale H and Bamberger C: A novel protein with strong homology to the tumor suppressor p53. Oncogene 15: 1363-1367, 1997.
18. Jost CA, Marin MC and Kaelin WG: p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
19. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316, 1998.
20. Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, et al: From p63 to p53 across p73. FEBS Lett 490: 163-170, 2001.
21. Jin P, Hardy S and Morgan DO: Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141: 875-885, 1998.
22. Laronga C, Yang HY, Neal C and Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106-23112, 2000.
23. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
24. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al: Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058, 2000.
25. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, et al: Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res 55: 6166-6171, 1995.
26. Henkels KM and Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083, 1999.
27. Wu GS and Ding Z: Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21: 1-8, 2002.
28. Troy CM, Stefanis L, Prochiantz A, Greene LA and Shelanski ML: The contrasting roles of ICE family proteases and interleukin-1 beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA 93: 5635-5640, 1996.
29. Chang C and Werb Z: The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11: 37-43, 2001.
30. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L and Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 19: 193-207, 2002.
31. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, et al: Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166: 2171-2177, 2001.
32. Tanimoto H, Yan Y, Clarke J, Clarke J, Korourian S, Shigemasa K, et al: Hepsin, a cell surface serine protease identified in hepatoma cells, is expressed in ovarian cancer. Cancer Res 57: 2884-2887, 1997.
33. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM and Kisiel W: Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 79: 876-877, 1998.
34. Xuan JA, Schneider D, Toy P, Lin R, Newton A, Zhu Y, et al: Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 66: 3611-3619, 2006.
35. King KL and Cidlowski JA: Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 58: 175-180, 1995.
36. 2-M arrest: evidence of commitment to apoptosis rather than mitotic death. Clin Cancer Res 6: 3756-3765, 2000.
37. 2 delay potentiates cell death by apoptosis and/or induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 3: 1371-1378, 1997.
38. Maeda T, Chong MT, Espino RA, Chua PP, Cao JQ, et al: Role of p21 (Waf-1) in regulating the G1 and G2/M checkpoints in ultraviolet-irradiated keratinocytes. J Invest Dermatol 119: 513-521, 2002.
39. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, et al: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
40. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10: 2687-2693, 2004.